vimarsana.com
Home
Live Updates
Data From Phase 3 Trials Demonstrate Efficacy of Dupilumab f
Data From Phase 3 Trials Demonstrate Efficacy of Dupilumab f
Data From Phase 3 Trials Demonstrate Efficacy of Dupilumab for Treating COPD, Type 2 Inflammation
Patients with uncontrolled chronic obstructive pulmonary disease (COPD) and type 2 inflammation had significantly better lung function at least a year into a dupilumab regimen.
Related Keywords
Ivelin Radkov ,
Naimish Patel ,
Georged Yancopoulos ,
European Medicines Agency ,
Global Development ,
Copd ,
Phase 3 Trials ,
Dupilumab ,
Type 2 Inflammation ,